First Warning Systems (FWS) announced that it has received $540,000 as the lead in to the company’s Series A funding round of $10 million. The initial investment group is a syndicate of investors primarily from Singapore, as well as a major lead by Steven Welch, an influential private investor based in Reno, Nevada.

FWS’ patented intelligent predictive models are projected to improve accuracy for breast cancer assessment to over 75%.The company’s BioMedia system uses a small data collection device placed under a bra to collect 2-12 hours of breast cell data (dynamic cell chaos). Circadian rhythm-based temperature variances of cell cycles are then measured through a patented process to identify abnormalities at the earliest stages of cell augmentation, the results of which are transferred through a smart device to a global cancer library.

With extensive clinical trials and years of advanced algorithm refinement completed, FWS’ patented intelligent predictive models are projected to improve accuracy for breast cancer assessment to over 75%. Unlike mammography and ultrasound, which image tissue characteristics, the FWS system measures tissue alterations at the cellular level allowing for early cancer prediction for women of all ages and tissue types.

Looking forward, the FWS system is intended to reduce the number of potentially unnecessary biopsy procedures, while refining the need for surgeries.